Tender detail
Crizotinib-containing tyrosine kinase inhibitor
Summary
The University Hospital Ostrava and the University Hospital Hradec Králové are procuring recurring deliveries of a crizotinib-containing tyrosine kinase inhibitor in 200 mg and 250 mg hard capsules. The contract covers a 48-month supply, with an estimated value of CZK 7,962,966.53.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.